NGM Biopharmaceuticals Inc (DELISTED) (NGM:DL)
1.54
0.00 (0.00%)
USD |
NASDAQ |
Apr 05, 16:00
Price Chart
Key Stats
Price and Performance | |
---|---|
Market Cap | 128.53M |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | -60.81% |
Valuation | |
PE Ratio | -- |
PE Ratio (Forward) | Upgrade |
PS Ratio | 28.76 |
Price to Book Value | 0.8647 |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | -- |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | 0.00 |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | 98.12% |
Profile
NGM Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics based on scientific understanding of key biological pathways for the treatment of cardio-metabolic, liver, oncologic and ophthalmic diseases. The company's products include, NGM313 (MK-3655), NGM120, NGM621, and NGM395 among others. These are focused on NASH, diabetes, oncology, AMD and metabolic disease. |
URL | https://www.ngmbio.com |
Investor Relations URL | https://ir.ngmbio.com/ |
HQ State/Province | California |
Sector | |
Industry | |
Equity Style | Small Cap/Value |
Next Earnings Release | May. 03, 2024 (est.) |
Last Earnings Release | Mar. 11, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |
Ratings
Profile
NGM Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics based on scientific understanding of key biological pathways for the treatment of cardio-metabolic, liver, oncologic and ophthalmic diseases. The company's products include, NGM313 (MK-3655), NGM120, NGM621, and NGM395 among others. These are focused on NASH, diabetes, oncology, AMD and metabolic disease. |
URL | https://www.ngmbio.com |
Investor Relations URL | https://ir.ngmbio.com/ |
HQ State/Province | California |
Sector | |
Industry | |
Equity Style | Small Cap/Value |
Next Earnings Release | May. 03, 2024 (est.) |
Last Earnings Release | Mar. 11, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |